Display options
Cite
Brinkschmidt C, Christiansen H, Terpe HJ, et al. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol. 2001;36(1):11-3doi: 10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M.
Brinkschmidt, C., Christiansen, H., Terpe, H. J., Simon, R., Lampert, F., Boecker, W., & Dockhorn-Dworniczak, B. (2001). Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Medical and pediatric oncology, 36(1), 11-3. https://doi.org/10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M
Brinkschmidt, C, et al. "Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome." Medical and pediatric oncology vol. 36,1 (2001): 11-3. doi: https://doi.org/10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M
Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W, Dockhorn-Dworniczak B. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol. 2001 Jan;36(1):11-3. doi: 10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M. PMID: 11464859.
Copy Download .nbib Format: NLM
Share it on

Med Pediatr Oncol. 2001 Jan;36(1):11-3. doi: 10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M.

Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.

Medical and pediatric oncology

C Brinkschmidt, H Christiansen, H J Terpe, R Simon, F Lampert, W Boecker, B Dockhorn-Dworniczak

Affiliations

  1. Department of Pathology, University of Münster, Germany. [email protected]

PMID: 11464859 DOI: 10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M

Abstract

PROCEDURE: To establish the significance of chromosome 17 aberrations in the biology of neuroblastomas, the fresh-frozen material of 53 primary neuroblastomas (average patient age: 20.8 months; stage 1 or 2: n = 10; stage 3: n = 10; stage 4: n = 10; stage 4s: n = 23) was studied by means of comparative genomic hybridization (CGH). Follow-up data were available for 52 of 53 cases studied (average follow-up period: 26.4 months). Except for one, all cases had previously been analyzed for MYCN status (semiquantitative Southern blot analysis). Studies of LOH 1p36 (VNTR-PCR) had been performed on 28 of 53 cases.

RESULTS: Chromosome 17 gains were detected in 46 of 53 (86.8%) cases. Whole chromosome gains were mostly restricted to localized tumors (stage 1 or 2: 9 of 10 cases; stage 4s:19 of 23; stage 3: 2 of 10; stage 4:0 of 10 cases), whereas distal 17 gains were significantly associated with clinically advanced tumor stages and patients aged over 1 year at diagnosis. Univariate analyses revealed a statistically significant correlation of distal 17q gains with overall survival (P< 0.01, MYCN amplification: P< 0.01; 1p deletion: P< 0.01) and an elevated recurrency rate (17q: P= 0.02, MYCN amplification: P = 0.05; 1p deletion P= 0.3). There was a strong coincidence of distal 17q gains and 1p deletion or MYCN amplification (P < 0.01).

CONCLUSION: Our data indicate that distal chromosome 17q gains are of major prognostic relevance for neuroblastoma patients. However, studies on a larger series of tumors have to be performed to assess whether or not these alterations are independent prognostic markers of a poor clinical outcome.

MeSH terms

Publication Types